Guest Professor Dahyot-Fizelier discusses the study on Ceftriaxone for preventing pneumonia in brain injury patients. Other topics include SCCM conference, intubation timing, and steroids in ARDS.
A single dose of Ceftriaxone has shown to significantly reduce the incidence of early ventilator-associated pneumonia (VAP) in patients with acute brain injury, leading to increased ventilator-free days, antibiotic-free days, and lower mortality rates.
Implementation of a single dose of Ceftriaxone as a preventive measure for early VAP in patients with acute brain injury may improve outcomes, but it is crucial to consider broader implications such as antibiotic stewardship and ecological impact.
Deep dives
Study finds single dose of Ceftriaxone reduces early ventilator-associated pneumonia (VAP)
A recent study published in The Lancet Respiratory Medicine examined the use of a single dose of Ceftriaxone in reducing the incidence of early ventilator-associated pneumonia (VAP) in patients with acute brain injury. The study enrolled patients with a Glasgow Coma Scale (GCS) of 12 or less who were expected to be intubated for at least two days and had a diagnosis of head trauma, stroke, or subarachnoid hemorrhage. The results showed a significant decrease in the incidence of early VAP in the Ceftriaxone group compared to the placebo group. Additionally, the Ceftriaxone group had more ventilator-free days and antibiotic-free days, as well as lower mortality rates, both at 28 days and at 60 days. These findings suggest that a single dose of Ceftriaxone may be an effective strategy for preventing early VAP in patients with acute brain injury.
Understanding the importance of early VAP and the heterogeneity of patient populations
The study defined early VAP as occurring between days two and seven of intubation, although the definition may differ from typical perceptions of early VAP. It is worth noting that the patient population in the study was selected and excluded certain types of patients, such as those with comatose conditions or prior antibiotic usage. These factors may limit the generalizability of the findings. However, the study demonstrated benefits beyond the reduced incidence of VAP, including increased ventilator-free days, antibiotic-free days, and lower mortality rates. The use of a single dose of Ceftriaxone in patients with acute brain injury resulted in improved outcomes and suggests the potential for implementing this strategy to prevent early VAP in similar patient populations.
Consideration of antibiotic stewardship and ecological impact
While the study demonstrated positive outcomes with a single dose of Ceftriaxone, it is important to consider the broader implications, such as antibiotic stewardship and potential ecological impact. The reduction in VAP incidence may lead to a decrease in microbiological cultures and subsequent antibiotic use, which can have implications on the healthcare system and blood availability. Additionally, future research is needed to understand the mechanisms behind these outcomes and identify specific patient populations that may benefit the most from this approach.
Episode 30! This episode is a little different. We recap the SCCM conference first. THEN we go into PROPHY-VAP or "Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury" published January 2024 by Professor Dahyot-Fizelier in Lancet Respiratory Medicine. Then we dive into our long neglected mailbag to review listener questions about MINT, intubation timing, ACORN, and all the steroids in ARDS talk
PROPHY-VAP: https://pubmed.ncbi.nlm.nih.gov/38262428/ SCCM Steroid guidelines: https://pubmed.ncbi.nlm.nih.gov/38240492/ Counter-Point should we use steroids in ARDS: https://pubmed.ncbi.nlm.nih.gov/33422201/ sRAGE in NIV and HFNC: https://pubmed.ncbi.nlm.nih.gov/38250011/ Anaerobes in Aspiration: https://pubmed.ncbi.nlm.nih.gov/37250794/ Anaerobes in Gut: https://pubmed.ncbi.nlm.nih.gov/36229047/
If you enjoy the show be sure to like and subscribe, leave that 5 star review! Be sure to follow us on the social @icucast for the associated figures, comments, and other content not available in the audio format! Email us at icuedandtoddcast@gmail.com with any questions or suggestions! Thank you Mike Gannon for the intro and exit music!
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode